Pioglitazone Special Drug Use Surveillance "Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus"

• Sponsor: Takeda
• Information provided by (Responsible Party): Takeda

Study Description

Brief Summary:

The purpose of this survey is to determine the onset of new cerebral and cardiovascular events and changes in metabolic syndrome parameters in patients with type 2 diabetes mellitus on long-term pioglitazone (Actos Tablets) treatment.

Condition or disease	Intervention/treatment
Type 2 Diabetes Mellitus	Drug: Pioglitazone

Detailed Description:

This is a special drug use surveillance on long-term use of pioglitazone (Actos Tablets) in patients with type 2 diabetes mellitus, designed to determine the onset of new cerebral and cardiovascular events and changes in metabolic syndrome parameters, and to analyze the association between patient baseline characteristics, including any metabolic syndrome-related risk factors, and the onset of new cerebral and cardiovascular events in an exploratory setting.

Participants will be patients with type 2 diabetes mellitus. The planned sample size is 20000.

The usual adult dosage is 15 to 30 mg of pioglitazone administered orally once daily before or after breakfast.

Study Design

Layout table for study information

Study Type :	Observational
Actual Enrollment :	18223 participants
Observational Model:	Cohort
Time Perspective:	Prospective
Official Title:	Actos Tablets Special Drug Use Surveillance "Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus"
Actual Study Start Date :	October 16, 2007
Actual Primary Completion Date :	June 30, 2013
Actual Study Completion Date :	June 30, 2013

Groups and Cohorts

Group/Cohort	Intervention/treatment
Pioglitazone 15 to 30 mg; administered orally once daily before or after breakfast for 3 years.	Drug: Pioglitazone; Pioglitazone tablets; Other Name: ACTOS

Outcome Measures

Primary Outcome Measures :

1. Percentage of Participants Who Met at Least One New Cerebral and Cardiovascular Events [ Time Frame: From Baseline, Up to 3 Years ]
   Cerebral and cardiovascular events (Macroangiopathy) include the following: Sudden death, Cerebral infarction, Cerebral hemorrhage, Subarachnoid hemorrhage, Acute myocardial infarction, Angina pectoris requiring intervention or hospitalization for treatment, Cardiac failure requiring hospitalization for treatment, Atrial fibrillation, Aortic dissection. Reported data was frequency of participants who met at least one new cerebral and cardiovascular event throughout this study.
2. Changes From Baseline in Metabolic Syndrome Parameters (Body Weight) at Final Assessment Point [ Time Frame: From Baseline and final assessment point (Up to 3 Years) ]
   Changes from baseline in metabolic syndrome parameters at final assessment point (up to 3 years) were reported. The reported data on this outcome measure is in body weight as a one of metabolic syndrome parameters and for each gender (male/female).
3. Changes From Baseline in Metabolic Syndrome Parameters (Waist Circumference) at Final Assessment Point [ Time Frame: From Baseline and final assessment point (Up to 3 Years) ]
   Changes from baseline in metabolic syndrome parameters at final assessment point (up to 3 years) were reported. The reported data on this outcome measure is in waist circumference as a one of metabolic syndrome parameters and for each gender (male/female).
4. Changes From Baseline in Metabolic Syndrome Parameters (Haemoglobin A1c (HbA1c) [National Glycohemoglobin Standardization Program (NGSP)]) at Final Assessment Point [ Time Frame: From Baseline and final assessment point (Up to 3 Years) ]
   Changes from baseline in metabolic syndrome parameters at final assessment point (up to 3 years) were reported. The reported data on this outcome measure is in HbA1c (NGSP) as a one of metabolic syndrome parameters.
5. Changes From Baseline in Metabolic Syndrome Parameters (Fasting Blood Glucose) at Final Assessment Point [ Time Frame: From Baseline and final assessment point (Up to 3 Years) ]
   Changes from baseline in metabolic syndrome parameters at final assessment point (up to 3 years) were reported. The reported data on this outcome measure is in fasting blood glucose as a one of metabolic syndrome parameters.
6. Changes From Baseline in Metabolic Syndrome Parameters (Fasting Blood Insulin Level) at Final Assessment Point [ Time Frame: From Baseline and final assessment point (Up to 3 Years) ]
   Changes from baseline in metabolic syndrome parameters at final assessment point (up to 3 years) were reported. The reported data on this outcome measure is in fasting blood insulin level as a one of metabolic syndrome parameters.
7. Changes From Baseline in Metabolic Syndrome Parameters (Total Cholesterol Level) at Final Assessment Point [ Time Frame: From Baseline and final assessment point (Up to 3 Years) ]
   Changes from baseline in metabolic syndrome parameters at final assessment point (up to 3 years) were reported. The reported data on this outcome measure is in total cholesterol level as a one of metabolic syndrome parameters.
8. Changes From Baseline in Metabolic Syndrome Parameters (High-density Lipoprotein (HDL) Cholesterol Level) at Final Assessment Point [ Time Frame: From Baseline and final assessment point (Up to 3 Years) ]
   Changes from baseline in metabolic syndrome parameters at final assessment point (up to 3 years) were reported. The reported data on this outcome measure is in HDL cholesterol level as a one of metabolic syndrome parameters.
9. Changes From Baseline in Metabolic Syndrome Parameters (Fasting Triglyceride Level) at Final Assessment Point [ Time Frame: From Baseline and final assessment point (Up to 3 Years) ]
   Changes from baseline in metabolic syndrome parameters at final assessment point (up to 3 years) were reported. The reported data on this outcome measure is in fasting triglyceride level as a one of metabolic syndrome parameters.
10. Changes From Baseline in Metabolic Syndrome Parameters (Systolic Blood Pressure) at Final Assessment Point [ Time Frame: From Baseline and final assessment point (Up to 3 Years) ]
    Changes from baseline in metabolic syndrome parameters at final assessment point (up to 3 years) were reported. The reported data on this outcome measure is in systolic blood pressure as a one of metabolic syndrome parameters.
11. Changes From Baseline in Metabolic Syndrome Parameters (Diastolic Blood Pressure) at Final Assessment Point [ Time Frame: From Baseline and final assessment point (Up to 3 Years) ]
    Changes from baseline in metabolic syndrome parameters at final assessment point (up to 3 years) were reported. The reported data on this outcome measure is in diastolic blood pressure as a one of metabolic syndrome parameters.

Secondary Outcome Measures :

1. Changes From Baseline in HbA1c (NGSP) With Number of Metabolic Syndrome-related Risk Factor (MetS-related Factor) at Final Assessment Point [ Time Frame: From Baseline and final assessment point (Up to 3 Years) ]
   Changes from baseline in HbA1c (NGSP) with number of MetS-related factor were reported instead. Risk factors included Glucose Intolerance, Complication of Hypertension, Complication of Hyperlipidemia, Obesity, and Family History of Diabetes in Second-Degree Relatives.
2. Association Between Patient Baseline Characteristics, Including Any Metabolic Syndrome-related Risk Factors, and Onset of New Cerebral and Cardiovascular Events [ Time Frame: 3 Years ]

Eligibility Criteria

Layout table for eligibility information

Ages Eligible for Study:	20 Years to 74 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Type 2 diabetes mellitus

Criteria

Inclusion Criteria:

• Patients must have type 2 diabetes mellitus and have undergone measurements for all of the following parameters to be included in this survey:

Waist circumference, height, body weight, blood pressure, Haemoglobin A1c (HbA1c), fasting triglyceride, High-density Lipoprotein (HDL)-cholesterol

Exclusion Criteria:

• Patients meeting any of the following criteria (1) to (5) will be excluded:

  1. Patients with any contraindications to pioglitazone (Actos Tablets) treatment as specified below:

     Cardiac failure, history of cardiac failure, severe ketosis, diabetic coma or precoma, type 1 diabetes mellitus, serious hepatic dysfunction, serious renal dysfunction, severe infection, perioperative state, serious trauma, history of hypersensitivity to any ingredients of pioglitazone (Actos Tablets), pregnancy or possible pregnancy

  2. Patients aged < 20 or ≥ 75 years
  3. Patients who currently have or have had any of the following: myocardial infarction, angina pectoris, cardiomyopathy, hypertensive heart disease (including left ventricular hypertrophy with cardiac hypofunction*), atrial fibrillation, atrial flutter, valvular disease, aortic dissection, cerebral infarction, cerebral hemorrhage (including subarachnoid hemorrhage). (*Reduced cardiac function is roughly defined as having a brain natriuretic peptide [BNP] ≥ 40 pg/mL.)
  4. Patients who have taken pioglitazone (Actos Tablets) within 3 months before enrollment in this survey
  5. Patients who have been enrolled in the candesartan cilexetil (Blopress) special drug use surveillance "hypertension: survey on metabolic equivalents (MetS) (Challenge-MetS)" at each medical institution.

Contacts and Locations

Sponsors and Collaborators

Takeda

Investigators

Layout table for investigator information

Study Director:	Study Director	Takeda

More Information

Layout table for additonal information

Responsible Party:	Takeda
ClinicalTrials.gov Identifier:	NCT02002975 History of Changes
Other Study ID Numbers:	237-016; JapicCTI-132328 ( Registry Identifier: JapicCTI )
First Posted:	December 6, 2013
Results First Posted:	January 24, 2019
Last Update Posted:	January 24, 2019
Last Verified:	August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:		No
Studies a U.S. FDA-regulated Device Product:		No

Keywords provided by Takeda:

Drug Therapy

Additional relevant MeSH terms:

Layout table for MeSH terms

Diabetes Mellitus; Diabetes Mellitus, Type 2; Metabolic Syndrome; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases	Insulin Resistance; Hyperinsulinism; Pioglitazone; Hypoglycemic Agents; Physiological Effects of Drugs